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RatsFew data are available on adolescent users because most behavioral studies on anabolic–androgenic steroids
(AAS) abuse have been performed in adults. Studies evaluating the impact of long-term effects of AAS abuse
on the prepubertal phase are evenmoreuncommon.Accordingly, this studywas developed to test thehypothesis
that changes induced by the use of AAS during the adolescent phase may be noted in the adult phase evenwhen
the AAS treatment cycle is discontinued. Therefore, not only behavioral changes but also possible autonomic and
electrolyte disorders were evaluated. For this purpose, we used male prepubertal, 26-day-old (P26) Wistar rats
that were treated with vehicle (control, n = 10) or testosterone propionate (TP; 5 mg/kg intramuscular (IM)
injection, AAS, n = 10) ﬁve times per week for 5 weeks, totaling 25 applications during the treatment. Aggres-
sion tests were performed at the end of the cycle (P54–56), whereas open-ﬁeld tests (OFTs), elevated plus maze
(EPM) behavioral tests and measurements of heart rate variability (HRV), ﬂuid intake and pathology were
conducted in the adult phase (P87–92). The AAS group showed greater aggressiveness in the pubertal phase
and higher levels of horizontal and vertical exploration and anxiety-related behavior in the adult phase than
the control group (P b 0.05). HRV tests showed an increase in sympathetic autonomic modulation, and
hydroelectrolytic assessment showed lower basal intake levels of hypertonic saline than the control group
(P b 0.05), without statistically signiﬁcant changes in the basal intake of water. These data together suggest
that the use of AAS during the prepubertal phase induces behavioral, autonomic and hydroelectrolytic changes
that manifest in the adult phase even when treatment is discontinued in late adolescence in rats.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Anabolic–androgenic steroids (AAS) are synthetic derivatives of
testosterone with four-ring structures consisting of 19 carbon atoms.
There are approximately 60 different AAS available, and these mole-
cules vary in their chemical structure and, as a result, in their metabolicisiológicas, Instituto de Biologia,
, 23851-000, Seropédica, Rio de
1763.
ghts reserved.and physiological effects [1,2]. Some studies report that more than one
million Americans have used AAS [3]. Although some athletes use AAS
to be successful, use is not restricted to them, and AAS abuse in adoles-
cents has dramatically increased [4]. This is related to the supposed
enhancement of physical appearance and athletic performance by AAS
[5].
The 2003 Youth Risk Behavior Surveillance System showed that 5.3%
to 6.8% of adolescents have used AAS at some point in their lives.
Furthermore, it has been reported that adolescents aremore susceptible
to the deleterious effects of AAS [5]. These side effects include
unprovoked and indiscriminate aggression [6] and impulsiveness [7].
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induced by AAS injected during adolescence. For example, Farrell and
McGinnis [8] showed that male rats exposed to AAS during puberty
were more aggressive towards male rats (resident or intrusive oppo-
nent) during aggressive encounters [9].
Cardiovascular dysfunction, including sudden cardiac death, is one
of the main side effects associated with AAS abuse, both in AAS users
and animal models of AAS abuse, concomitant with the behavioral
changes observed [10–13].
Although several studies have showndirect cardiac changes induced
by AAS, including ventricular hypertrophy associated with diastolic
dysfunction [14,15], thrombosis andmyocardial infarction [16,17], indi-
rect effects of AAS on heart morphology and function are difﬁcult to
exclude. Thus, the cause and effect relationship between the heart and
other tissues remains unclear in the literature. For example, an increase
in peripheral resistance/blood pressure has long been observed in stud-
ies of experimental models of AAS abuse [18,19].
Cardiac arrhythmias and sudden death are also associated with AAS
abuse [20,21], and some authors argue that cardiac electrophysiological
changes may not only be attributed to myoﬁbrillar disorders, tissue
necrosis and ﬁbrosis, among other factors, but other indirect mecha-
nisms may also exist that cause these effects on heart excitability [22].
Therefore, identifying the extra-cardiac sites affected by AAS abuse
may bring new perspectives and help establish the main mechanisms
underlying cardiac abnormalities induced by AAS.
Pereira-Junior et al. [22] ﬁrst reported cardiac autonomic dysfunc-
tion as a potential mechanism underlying cardiac dysfunction and
sudden death associatedwith AAS abuse in adult rats [22]. This is unsur-
prising when considering that sympathetic hyperactivity is a mecha-
nism known to generate cardiac arrhythmias, given the decreased
ventricular ﬁbrillation threshold [23].
Therefore, adverse effects on the electrophysiological responses to
sympathetic hyperactivity may contribute to the development of a
proarrhythmic substrate [24]. An excess of androgens has already
been related to increased sympathetic tone [25]. Together, these data
led us to recognize that AAS abuse may trigger chain events that even-
tually cause sudden death induced by sympathetic hyperactivity.
It has not been studied thus far whether the possible AAS-induced
autonomic imbalance persists throughout the adult life period of rats
treated with AAS during the adolescent phase. In this studywe evaluat-
ed the effects of testosterone not only on heart rate variability but also
on ﬂuid intake and the behavior of adult rats treated with testosterone
during the adolescent life period.
Our hypothesis is that AAS abuse during this critical period of time
may alter not only animal behavior in the adolescent phase but also
affect the behavior, heart function and hydroelectrolytic balance in the
adult phase of rats because adolescence is a critical period of brain
development, partly due to increased hormone levels [26].
2. Material and methods
The present study was conducted according to the “Guide for the
Care and Use of Laboratory Animals” (NIH Publication No. 85–23,
revised in 1996), and the experimental protocols were approved by
the Ethics Committee on Animal Use of the Federal Rural University
of Rio de Janeiro in accordance with Brazilian law (Law No. 11.794 of
October 8, 2008).
2.1. Animals
Forty intact maleWistar rats, with initial bodyweights between 110
and 130 g, were used in the present study. All animals were housed in
cages (four to ﬁve animals/cage) under controlled temperature
(22 ± 2 °C), with daily exposure to a 12-hour light–dark cycle (lights
off at 7:00 pm) and free access to water and standard chow.In addition, older and heavier male animals, initially with body
weights of approximately 450 g (n = 10), remained housed through-
out the experiment with ovariectomized females weighing approxi-
mately 250 g (n = 10), except during the aggression test, at which
time the females were removed from the box immediately before the
interaction betweenmales intended to stimulate their partner's territo-
rial aggressiveness (see below). Males in the company of ovariecto-
mized females were housed in plastic boxes (35 × 50 × 35 cm). To
stimulate territorial aggressiveness, these males received training (ﬁve
times per week) with other sparring animals (lighter and younger;
approximately 200 g and 50 days old) for 10 min daily, with weekly
rotations of their respective opponents, for four consecutive weeks.
2.2. Experimental design
Prepubertal (postnatal day 26, P26) male rats were randomly dis-
tributed into two groups: the TP group (AAS, n = 20) received testos-
terone propionate (TP; Perinon®, Perini-Brasil Laboratory, 5 mg kg−1
body weight), and the control group (Control, n = 20) received an
equal volume of vehicle (corn oil); both were given intramuscularly
(always between 10:00 and 11:00 am) as ﬁve injections per week for
5 weeks as previously described [27]. The dose of AAS used in the
present study is equivalent to the dose used in humans to reach a high
muscle weight gain during AAS abuse. The treatments were discon-
tinued after 5 weeks of AAS or vehicle injections to assess the long-
term effects of AAS administered during the prepubertal/pubertal
phase of rats. The aggression tests were conducted in the ﬁnal week of
treatments (P54–56) in 20 animals (n = 10/group), whereas the be-
havioral, heart rate variability (HRV) and ﬂuid intake tests (all described
next) were performed in other 20 rats (n = 10/group) during their
adult life (P84–90), ~3–4 weeks after the ﬁnal day of treatment in
both groups. The reason for using different subsets of animals in aggres-
sion test and behavioral, autonomic and hydroelectrolytic studies is be-
cause aggressive stimulus could inﬂuence the other parameters and
lead to misleading results. Postmortem study (pathology) was per-
formed at the end of the protocol (P92) as shown in Fig. 1.
2.3. Behavioral studies
2.3.1. Aggression tests
The aggression test consisted of placing the intruder and resident
rats alone for 10 min in a clean polypropylene box with a closed, high
and transparent acrylic lid, without the availability of food and water.
The aggressiveness of the intrusive rat was observed during the test
using a scoring system, wherein a score was tallied each time the rat
performed one of the following tasks: 1. Attack threat, 2. Attacks by
bites, 3. Attacks by sideways kicks, 4. Attacks by boxing, 5. Pelvic pres-
sure or 6. Position of dominance. The testswere performed at the begin-
ning of the last week of the TP cycle and were recorded for further
individual analysis off-line [27].
2.3.2. Open-ﬁeld test (OFT)
We used a quadrangular open ﬁeld (100 × 100 × 30 cm) split into
25 equal quadrants to assess the exploratory activity of animals as pre-
viously reported by our group [28]. Brieﬂy, the experimental assay
started at 7 pm and was conducted in a dark room with a red light.
Each animal was individually placed in the center of the open ﬁeld at
the beginning of the test, and the following parameters were recorded:
1. Locomotor activity (the number of times the animal invaded with all
four legs in one of the arena ﬁelds): counted as the total number of
squares crossed; 2. Rearing (animal standing on his hind legs with the
torso perpendicular to the ﬂoor and his head pointing upwards, touch-
ing or not touching thewalls of the open ﬁeldwith the forefeet); 3. Time
of inactivity: recorded as total time without movement; and 4.
Grooming episodes (number of movements performed with one or
both front or hind legs towards the mouth or head, which may be
Fig. 1. Experimental protocol. In postnatal day 26 (P26), male rats were randomly distributed into two groups: AAS (n = 20) received testosterone propionate (5 mg kg−1 body weight)
and the control group (n = 20) received an equal volume of vehicle (IM) as ﬁve injections per week for 5 weeks. Note that the treatments were discontinued after 5 weeks of AAS or
vehicle injections to assess the long-term effects of AAS administered during the prepubertal/pubertal phase of rats. AAS = anabolic–androgenic steroids.
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directed towards the lateral portions of the body and genital area),
which was counted as 4.1 Total number of grooming activities and 4.2
Grooming time (time spent performing grooming activities), counted
as total time spent performing grooming.
The area was cleaned with a 5% ethanol solution between each test.
The locomotor activity was recorded during the testing period, and the
elements of exploratory activity were scored by observation and count-
ed off-line.
2.3.3. Elevated plus maze (EPM) test
The elevated plus maze (EPM) test validated by Pellow et al. [29]
was performed to evaluate animal anxiety. Brieﬂy, the apparatus used
consisted of two opposing open arms (50 × 10 × 40 cm) and two
closed arms (50 × 10 × 1 cm), also opposing, in the form of a Greek
cross, connected by a central platform (10 × 10 cm) 50 cm above the
ﬂoor level [29,30]. The test was conducted under a dim red light (5 lx).
The animals were placed in the center of the apparatus with the
head turned to one of the closed arms, and their behavior was observed
for 5 min. The following parameters were assessed: 1. Number of
closed-arm entries; 2. Time spent in the closed arms; 3. Number of
entries into the open arms; 4. Time spent in the open arms; and the
ethological parameters: 5. Number of emergences and 6. Number of
self-grooming activities [31].
2.4. HRV and spectral analysis study
Electrocardiograms (ECGs) were performed in animals from both
experimental groups. Twenty-four hours before the assessment, the
animals were immobilized and shaved across the chest length, and a
foam electrode (3 M do Brasil LTDA, Sumaré-SP, Brazil) approximately
1.5 cm in diameter was attached to each hemithorax. The rats were
connected to the ECG acquisition system (Ampliﬁer MP100A CE,
BIOPAC SYSTEMS INC) moments before the recording of the ECG. The
signals were acquired at a sampling a frequency of 10 kHz and 12-bit
amplitude resolution, and the software AcqKnowledge® (version
3.8.1) was used to acquired and view the recordings.
All animals were rigorously evaluated during the same period of the
day (~7–9 h am) and in similar positions to collect the ECG data with
minimal interference from the circadian cycle.
The ECG recordings lasted 600 s, and the entire signal processing of
HRV was performed using Matlab-based algorithms [22] from the
Cardioseries software (Version1.1). Tachograms representing 600 s
were generated after the detection of the R wave peak by counting all
cardiac ﬂuctuations within this time period [22]. The parameters
assessed in the time domain were the following: 1. Heart rate, 2. Stan-
dard deviation of RR intervals and 3. Root mean square of successive
differences of RR intervals [22,32]. The tachograms were resampled to
equal intervals using the cubic interpolation method, at 10 Hz, and the
linear trend was removed for the spectral analysis of HRV (frequency
domain) [22,32]. The power spectrum was obtained with a rapid
decay based on the Fourier method (Welch's periodogram: 256 points,50% overlap and Hamming window). Spectral amplitudes were mea-
sured in two frequency bands: low frequency (LF: 0.2–0.8 Hz) and
high frequency (HF: 0.8–2.5 Hz); the power (ms2) was estimated as
the area under the spectrum within those frequency bands [22,32].
2.5. Hydroelectrolytic regulation
2.5.1. Measurement of water and sodium intake
Intact animals were acclimatized for 5 days in individual metabolic
cages with food and two polypropylene volumetric water bottle
drinkers (graduated in 0.1 ml), one containing water and the other
containing NaCl solution (1.8%), available ad libitum. Hypertonic saline
is normally unsavory for rats and humans. The ingestion of saline by rats
only occurswhen there is a deﬁcit in the Na+ concentration and volume
of body ﬂuids. The ﬂuid intake is expressed in ml/100 g bw for varying
periods, in minutes, according to the experimental protocol (60, 120,
180, 240 and 300 min).
2.5.2. Protocol of water and sodium depletion
Sodium depletion was performed by the administration of furose-
mide (subcutaneous (SC) administration) at a dose of 20 mg/kg once
the acclimatization period was completed. The animals were returned
to their cages after being washed immediately after the treatment to
remove traces of sodium. A low-sodium diet (corn meal) was provided
to the animals for 24 h before the experiment (intake response evalua-
tion). The cornmealwas removed after that period, and two glass water
bottle drinkers (graduated in 0.1 ml) with stainless steel nozzles con-
taining the same liquids from the acclimatization period were mounted
on the front of the metabolic cages. Furosemide is widely used as a
classic model of hyponatremia and hypovolemia induction in rats,
given its potent natriuretic/diuretic effect that induces sodium appetite
[33–37].
2.6. Body weight assessment and pathology
Body weight was measured just before the beginning of the experi-
ments (basal body weight: at P26), and at P60 and P92 in both groups.
At the end of study (P92) animals were weighed and euthanized by
decapitation. Thereafter, testicles, heart, lungs, liver, kidneys and adre-
nals were dissected, pruned from fat, weighed and the relative organ
weight calculated as: organ weight (mg)/body weight (g).
2.7. Statistical analysis
The results were expressed as mean ± SEM. Data were analyzed by
one-way or two-way analysis of variance (ANOVA) for repeated mea-
surements using the Graphpad Prism software (version 6, Graphpad
Software, Inc., San Diego, USA). It was performed a Shapiro–Wilk test
to evaluate the normality data distribution, and all variables had a
normal distribution. To detect signiﬁcant differences among the exper-
imental groups and weeks, ANOVAs were supported by the Bonferroni
post-hoc tests, only when overall effects were signiﬁcant (always the
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Values P b 0.05 or P b 0.01 were considered statistically signiﬁcant
and always represented post-hoc analysis after an overall effect was
detected by ANOVA.Fig. 2. Aggression test. Frequency of attacks, threats, pelvic trusts and position of domi-
nance for AAS and control male rats towards larger opponentmales during AAS or vehicle
exposure respectively (P54–56). Data represent the mean values ± S.E.M. from Control
(n = 10) and AAS (n = 10) groups. *P b 0.05 and **P b 0.01 vs. Control.3. Results
3.1. Body weight and pathology
Table 1 shows basal bodyweight (at P26) and its values in the fourth
(P60) and ninth (P92) weeks after the study began. Therewas no statis-
tically signiﬁcant difference in body weight between the groups over
time. The AAS group showed a signiﬁcant decrease in the relative
weight of testicles (P b 0.01) when compared with the control group
at the end of the experiment (P92), suggesting that anabolic steroids
were effective at blocking the hypothalamic–pituitary–gonadal axis
even when treatment was discontinued at early adulthood. Treatment
with TP did not affect the other pathological parameters observed,
including the relativeweight of the heart, lungs, liver, kidneys and adre-
nal glands (Table 1).3.2. Behavioral tests
3.2.1. Aggression test
Fig. 2 shows the results of aggression tests from all animals. As
shown, there was a statistically signiﬁcant increase in both the number
of attacks (6.80 ± 1.20 vs. 2.88 ± 1.10number of attacks, P b 0.05) and
threats (7.40 ± 2.16 vs. 2.22 ± 1.23number of attack threats, P b 0.05)
in AAS vs. control animals, respectively.
There was no statistically signiﬁcant difference between groups
(P N 0.05) for the other test parameters (pelvic pressure and submis-
sion). These data suggest an increase in aggressiveness induced by the
testosterone treatment one month after beginning the treatment
(P54–56), which was at the end of the cycle of testosterone injections.3.2.2. OFT
The locomotor activity was assessed using the number of squares
crossed and the number of rearing activities (vertical exploration) by
the animals. Fig. 3 shows the statistically signiﬁcant increase in thenum-
ber of quadrants crossed (185.6 ± 12.5 vs. 166.0 ± 10.6, P b 0.05) and
in the number of rearing activities (48.5 ± 1.5 vs. 42.2 ± 2.6, P b 0.05)
during the 5 min the rats were exposed to the OFT in the AAS vs. control
groups, respectively.
The time of inactivity may also be related to exploratory activity.
Fig. 3 shows that the AAS group showed a signiﬁcant decrease in this
parameter compared with the control group during the 5 min the rats
were exposed to the OFT (AAS: 19.4 ± 1.9 vs. control: 30.8 ± 2.6 s,
P b 0.01). This result also corroborates the number of quadrants crossedTable 1
Basal (P26), P60 and P92 body weight (BW), and relative (mg·g−1 BW) testicle, heart,
lung, liver, kidney and adrenal weight for Control and AAS group.
Parameters Groups
Control AAS
Basal (P26) BW (g) 106.03 ± 1.58 108.15 ± 1.68
P60 BW (g) 219.92 ± 2.57 229.18 ± 2.35
P92 BW (g) 359.62 ± 9.48 325.81 ± 8.43
Testicle (mg/g bw) 11.84 ± 0.37 7.61 ± 0.36⁎⁎
Heart (mg/g bw) 3.53 ± 0.20 3.45 ± 0.05
Lung (mg/g bw) 5.52 ± 0.18 5.68 ± 0.26
Liver (mg/g bw) 33.41 ± 0.45 32.60 ± 0.48
Kidney (mg/g bw) 7.06 ± 0.13 7.28 ± 0.18
Adrenal (mg/g bw) 0.17 ± 0.007 0.16 ± 0.007
Data are mean ± S.E.M. n = 10/group.
⁎⁎ P b 0.01 vs. control.and the rearing results previously shown; AAS treatment increased
motor and exploratory activitywhile decreasing the time of immobility.
The amount of fecal bolus may be related to animal anxiety. Fig. 3
shows that the production of fecal bolus increased in theAAS group dur-
ing the 5min they were exposed to the OFT (control: 3.6 ± 0.9 vs. AAS:
4.9 ± 0.6, P b 0.05).
The amount of fecal output, which may be related to anxiety, was
increased in adult animals even though the testosterone treatment
was only performed during the adolescent phase, as found in the loco-
motor/exploratory activity evaluation tests.3.2.3. EPM test
The number of closed-arm entries in the EPMmay also be used as a
measure of the animals' exploratory activity. Fig. 4 shows that the
animals from the AAS group showed an increase in the number of
closed-arm entries during 5 min compared with the control group
(control: 13.7 ± 1.2 vs. AAS: 28.3 ± 1.2 entries/5 min, P b 0.01), al-
though no difference was found in the time spent in the closed arms
compared with the control group (control: 233.6 ± 19.2 vs. AAS:
245.5 ± 20.4 s, P N 0.05). Conversely, the time spent by animals in
the open arms, often used as a parameter to evaluate anxiety, decreased
in the AAS group compared with the control group (control: 38.6 ± 3.1
vs. AAS: 32.0 ± 2.1 s, P b 0.05). The other parameters evaluated in the
maze were not signiﬁcantly different between groups (P N 0.05, data
not shown).Fig. 3. Open ﬁeld test. Frequency or time spent of squares crossed, rearings, inactivity
(time spent immobile) and fecal boli for AAS and control male rats assessed during their
adult life (P84). Data represent the mean values ± S.E.M. from Control (n = 10) and
AAS (n = 10) groups. *P b 0.05 and **P b 0.01 vs. Control.
Fig. 4. Elevated plus maze test. Frequency of entries in closed arms and time spent in
closed or open arms for AAS and control male rats assessed during their adult life (P84).
Data represent the mean values ± S.E.M. from Control (n = 10) and AAS (n = 10)
groups. *P b 0.05 and **P b 0.01 vs. Control.
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Although the animals' heart rate was not different between groups
(Fig. 5A), there was a statistically signiﬁcant decrease in HRV assessed
in the time domain parameters studied in the AAS group compared
with the control: 1. standard deviation of all normal RR intervals
(SDNN: 86.97 ± 6.15 for the AAS vs. 159.0 ± 8.10 ms for control,
P b 0.01) and 2. root mean square of successive differences between
adjacent normal RR intervals (RMSSD: 141.1 ± 14.6 for the AAS vs.
227.9 ± 15.34 ms for control, P b 0.01).
Regarding the HRV study in the frequency domain, Fig. 6 shows that
a statistically signiﬁcant decrease in high-frequency wave power was
found in the AAS group compared with the control (HF, AAS:
20.0 ± 3.27 vs. control: 53.75 ± 3.24 ms2, P b 0.01, Fig. 6B), although
no statistically signiﬁcant difference in low-frequency wave power
was found between the groups (LF, AAS: 45.81 ± 1.31 vs. control:
44.69 ± 1.61 ms2, P N 0.05, Fig. 6A). Consequently, together these
parameters signiﬁcantly increased the LF/HF ratio in the AAS group vs.
control: 2.82 ± 0.51 vs. 0.86 ± 0.07, respectively (P b 0.01, Fig. 6C).
These data suggest that testosterone administered during adoles-
cence altered the sympathetic–vagal balance toward increased sympa-
thetic modulation in the adult phase of rats.
3.4. Fluid intake study
The hydroelectrolytic homeostasis assessmentwas performed using
two experimental procedures. Initially, the animals were evaluated at
baseline conditions as shown in Fig. 7. No signiﬁcant differences were
found in water intake in the control and AAS groups in the time pe-
riods evaluated (Fig. 7B, P N 0.05). Conversely, there was a statisti-
cally signiﬁcant decrease in the intake of hypertonic saline in theFig. 5. Heart rate variability (time domain) study. Heart rate (A), standard deviation of RR int
control male rats assessed during their adult life (P87). Data represent the mean values ± S.E.AAS group compared with the control. This difference appeared at
180 min (Fig. 7A, AAS: 0.21 ± 0.03 vs. control: 0.50 ± 0.08 ml/100 g,
P b 0.001) and lasted until 300 min (AAS: 0.21 ± 0.03 vs. control:
0.56 ± 0.08 ml/100 g, P b 0.001). Conversely, the testosterone treat-
ment induced a reduction in the speciﬁc appetite for sodium by the
60-minute time period (Fig. 7C, AAS: 0.048 ± 0.019 vs. control:
0.34 ± 0.08, P b 0.01), and this reduction was maintained until the
last time period assessed (P b 0.01).
In spite of ﬂuid intake in the groups submitted to volume depletion,
no statistically signiﬁcant differences (P N 0.05) were found in either
dipsogenic or natriorexigenic response in the time periods evaluated
(data not shown).
We suggest that prolonged treatment with testosterone appears to
be critical in the tonic inhibition of sodium appetite at baseline condi-
tions. Treatment with testosterone does not appear to modulate
induced intake because such effect was not observed in homeostatic
challenge conditions.4. Discussion
The main ﬁnding of this study is the realization that behavioral, au-
tonomic and hydroelectrolytic alterations induced by TP are present in
adult rats, even when the administration of the anabolic steroid is initi-
ated in the prepubertal phase and discontinued at the onset of the adult
phase.
The intramuscular administration of TP in supraphysiological doses
for a ﬁve-week period resulted in no statistically signiﬁcant difference
in body weight between the treated group and the control group, in
contrast to the study by Cunningham and McGinnis [27], who noted a
drop in body weight in animals treated with AAS from the fourth
week, thus remaining the following week, compared with the control
treated with vehicle. This difference between our study and that of
Cunningham and McGinnis [27] may have resulted from differences in
the AAS administration protocol and the period of time in which body
weight was assessed. While we started the AAS treatment at P26 and
measured body weight only at P26, P60 and P92, Cunningham and
McGinnis [27] started at P40 and assessed bodyweight from P68 to P89.
The groups that received TP showed lower relative weights of
testicles (P b 0.05) when the values were corrected for their respective
body weights. This data suggests that testicular atrophy most likely re-
sulted from the inhibition of the hypothalamic–pituitary–gonadal axis
through anabolic steroid activity. Noorafshan et al. [38] found the
same level of reduction in testicular weight of animals, albeit in doses
and time periods greater than our protocol of AAS administration.
They also suggested that the explanation for this result may be, at
least partly, the establishment of a negative feedback loop in the hypo-
thalamus and pituitary gland of rats submitted to this treatment. It is
worth noting that the administrations of AAS in the present study
were started and discontinued before the adult phase, and surprisingly,
testicular atrophy was observed in the adult phase of rats treated withervals (B) and root mean square of successive differences of RR intervals (C) for AAS and
M. from Control (n = 10) and AAS (n = 10) groups. **P b 0.01 vs. Control.
Fig. 6.Heart rate variability (frequency domain) study. Low frequency (A), high frequency (B) and Low frequency/high frequency ratio for AAS and control male rats assessed during their
adult life (P87). Data represent themean values ± S.E.M. from Control (n = 10) and AAS (n = 10) groups. The power (ms2) was estimated as the area under the spectrumwithin those
frequency amplitudes. **P b 0.01 vs. Control.
Fig. 7. Measurement of basal ﬂuid intake. Cumulative hypertonic saline (A) and water
(B) intake (expressed as ml/100 g body weight) and preference for sodium (C) index
during 300 min for AAS and control male rats assessed during their adult life (P90).
Data represent the mean values ± S.E.M. from Control (n = 10) and AAS (n = 10)
groups. **P b 0.01 vs. Control.
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gland axis from the protocol of administrations used.
From the behavioral standpoint, users of high doses of AAS show a
high incidence and prevalence of psychiatric symptoms. The differences
in symptoms between users may be related to the dosage used. Thus,
more intense psychotic symptoms are associated with users who
consume more than 1000 mg of testosterone per week. However, the
symptoms usually disappear after discontinuation of AAS use, although
they may persist for up to a month even with adequate anti-psychosis
medication [39].
The results from the aggression test performed at the end of the
cycle of AAS injections indicated that the group treated with TP showed
a signiﬁcantly higher score than the control group for occasions of attack
(threats or effective). There was no statistically signiﬁcant difference in
the other test parameters (pelvic pressure and submission) between
groups (P N 0.05). These results corroborate the study by Breuer et al.
[40], who showed that TP administration in Long–Evans rats for
12 weeks (dose of 5 mg/kg/day ﬁve times weekly) signiﬁcantly in-
creased the aggressiveness of those animals compared with the control
group. A study by Lumia et al. [41] showed that treatment with testos-
terone (1 mg/kg, 3 times weekly) for 10 weeks in Long–Evans rats
increased dominant posture and reduced submissive posture compared
with control rats. Conversely, Breuer et al. [40] administered TP, nandro-
lone decanoate (ND) and stanozolol in Long–Evans rats (5 mg/kg, ﬁve
times a week for 12 continuous weeks), and aggressive behavior only
increased signiﬁcantly in the group treated with TP compared with its
control. The group treatedwithNDand its control group showed similar
levels of aggressiveness, and surprisingly, the group treated with
stanozolol showed signiﬁcantly lower levels of aggressiveness than
the other treated groups comparedwith their controls. This paradoxical
effect of stanozolol in abolishing aggressive behavior was attributed to
the different mechanisms of action of cellular and molecular targets of
AAS in the central nervous system (CNS). The study by McGinnis et al.
[42] showed that treatment with TP increased the rodents' aggressive-
ness associated with physical provocation of animals (through tail
pinch). The authors of this study speculated that TP sensitizes the ani-
mals to strike attacks on the intrusive animal and stimulates their
aggressiveness.
In contrast, the study by Long et al. [43] showed that Sprague–
Dawley rats receiving ND (2 mg/kg/day or 20 mg/kg/week for
4 weeks) showed higher levels of aggressiveness compared with the
control group. Male rats treated with ND showed dominance in the
access to the water bottle drinker compared with the control group
when using the competition test for water intake as a measure of
aggressiveness [44]. The study by McGinnis [45] showed that physical
provocation stimulates aggressiveness in rats treatedwith testosterone,
ND and stanozolol and is signiﬁcantly different from the control group.
However, animals treated with AAS showed no aggressive behavior in
the absence of physical provocation in any of the groups compared
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show that it causes changes in social interaction, speciﬁcally sexual and
aggressive behaviors [45–47]. However, these effects are contradictory
in nature because they depend on the type of androgen, dose adminis-
tered, length of treatment and animal line, age and sex [48].
In humans, the indiscriminate use of AAS is associated with behav-
iors including aggressiveness and violence without provocation. Chron-
ic use intensiﬁes aggressiveness, mainly through verbal aggression,
provocation to ﬁght and brawl and increased violence against women.
This type of use also contributes to elevated levels of homicides commit-
ted by teenagers. Adolescent users are more susceptible to acts of
violence, impatience, impulsiveness and irritability, and such effects
are positively correlated with serum levels of testosterone [45,49].
Controversially, some studies showed no evidence of AAS increasing
aggressiveness in healthy subjects when administered at high doses
[50,51]. In our study,we began treatmentwith AAS of rats prepubertally
and noted an increase in aggressive behavior by the ﬁfth week of treat-
ment, that is, with animals near the young-adult phase. The use of the
type of protocol used herein may explain differences from the results
found by other studies that observed no increase in aggressive behavior
of rats treated with AAS because their treatments began in the adult
phase of rats, as in the studies by McGinnis et al. [42] and Kindlundh
et al. [52].
We noted that an increase occurred in the OFT both in horizontal
exploration (number of squares crossed) and vertical exploration
(number of rearings), and there was a decrease in the time of inactivity
in animals treated with TP compared with the control. According to
Rygula et al. [53], changes in exploratory activity could be related to
changes in motivational state. It is noteworthy that the motivational
deﬁcit may be a presenting symptom in patients with depression. In
this context, these data may be related to the observation of the
Buddenberg et al. [54], who showed that testosterone administration
attenuated immobility in the forced swim test in rats in a dose-
dependent manner, indicating an antidepressant effect of the AAS in
this model.
Conversely, these results differ frommany other studies, which sug-
gest that AAS treatment does not change spontaneous locomotor activ-
ity [55–63]. Differences in the type of AAS, protocol, age of animals (that
is, the period during which the treatment is started) and the rat line
usedmay explain the discrepancies in the results found by the different
research groups aforementioned. It is worth noting that the open-ﬁeld
behavioral assessments in our study were performed in the adult
phase, whereas the AAS administration was performed beforehand in
the animals' prepubertal phase.
Although the OFT is used to evaluate anxiety-related behavior
through observation of animal exploration in the center and periphery
of the apparatus, the study by Ramos [64] reported thatmultiple behav-
ioral tests, including the EPM test,must be conducted for a better under-
standing of themechanism of emotional behavior in rodents. Therefore,
the EPM test is considered a quite useful and valid instrument to mea-
sure anxiety [29].
Some animal models of anxiety evoke fear-motivated or defensive
behaviors, analogous to anxious manifestations in individuals with
anxiety disorders, by simply exposing the animal to a new environment
or stimulus. The entries and time spent in the open and closed arms are
considered a reliable index of anxiety. Thus, the higher levels of anxiety
are, the lower percentage of open-arm entries and time spent in open
arms will be, and vice versa. The number of closed-arm entries may
also be positively correlated with the exploratory activity of animals
[65].
Very little is known about the effects of AAS on anxiety. The ﬁrst
study of these effects of AAS was performed by Bitran et al. [56], who
showed that high doses of TP alter the behavior of Long–Evans rats in
the EPM apparatus. In this study, the animals were tested after 6 and
14 days of treatment with TP. The animals increased their exploration
into the open arms after 6 days of treatment; that is, they showed ananxiolytic effect. However, animals treated with TP were not different
from the control group after 14 days of treatment. These results indicate
the transient anxiolytic character of the TP treatment. The few studies
that have addressed AAS and anxiety generally showed controversial
results [66,67].
In the present study, therewas a statistically signiﬁcant difference in
the number of entries into the closed arms and time spent in the open
arms between the groups in the EPM. Therefore, the changes observed
in the animals from the group treated with the AAS, speciﬁcally in-
creased exploratory behavior and anxiety-related behavior (anxiogenic
effect), are contrary to those observed in another study that noted an
anxiolytic effect induced by AAS [66]. Conversely, our results are similar
to those observed in the study by Kouvelas et al. [68]. In this study, the
authors treatedmaleWistar ratswithND at a dose of 15 mg/kg (s.c.) for
6 weeks daily. The study by Bing et al. [55] also showed an anxiolytic
effect in Wistar rats, albeit caused by a single injection of testosterone
(5 mg/kg), tested in the VOGEL'S test, 24 h after administering the
drug. The evaluation time in the maze used in the present study
(8 weeks after initiation of the treatment with the AAS) may not have
been adequate to evaluate a possible transient anxiolytic effect of the
AAS because TP promotes a short-term anxiolytic effect, as previously
described [66]. In any case, although the administration of the AAS
was performed in the prepubertal phase, the anxiogenic effect was
most interestingly observed in the adult phase despite the discontinua-
tion of treatment. Although neurochemical studies must be performed
in this model, it may be speculated that testosterone injected in a tem-
poral window important for thematuration of neural circuitry involved
in the regulation of speciﬁc types of behavior may have irreversibly
changed these animals' behavior in the adult phase.
Most organs receive sympathetic and parasympathetic innervations,
which often mediate opposing actions [69]. The autonomic nervous
system (ANS) affects the cardiovascular system tonically and reﬂexive-
ly, and modiﬁes cardiac output by changing the strength of contraction
of myocardial ﬁbers and heart rate. In the vessels, the ANS modiﬁes
vascular smooth muscle contractility and, thus, peripheral vascular
resistance [70]. Therefore, theANS is a keymechanismof bloodpressure
control. Alterations in this system may lead to dysautonomia, which
may adversely affect health. This change causes effects ranging from
occasional episodes of neurally mediated hypotension to progressive
neurodegenerative diseases. The increase in cardiac and renal sympa-
thetic tone causes the development of essential hypertension, and
cardiac sympathetic activation in chronic heart failure impairs myocar-
dial function. Several other disorders are related to autonomic dysfunc-
tion, including type II diabetes, chronic fatigue syndrome, visceral
obesity, dyslipidemia and Parkinson's disease, among others [69].
Studies of the direct effects of AAS administration on ANS activity are
scarce in the literature thus far. A study related stanozolol (a highly
potent anabolic androgenic steroid) with an increase in blood pressure
and a change in baroreﬂex activity, with no change in sympathetic
activity in animals treated with the drug [71]. Proposed mechanisms
for modifying cardiovascular reﬂex control include the synthesis of
nitric oxide (NO) and the central control of the vagus nerve, namely
increased glutamatergic activity in the hypothalamus and hippocam-
pus [71]. However, in a study from our group using ND, we observed
reduced vagal modulation and a tendency towards increased sympa-
theticmodulation after its administration [22]. Lastly, an experimental
study induced ischemia and ventricular ﬁbrillation in rats using doses
ranging from 40 to 160 mg/kg/min nandrolone by unclear mecha-
nisms [72]. Therefore, further research studies on this subject are
needed [39].
Several studies have previously shown increased activity of the sym-
pathetic nervous system (SNS) in models of anxiety, for example: Shaji
and Kulkarni [73] and Inagaki et al. [74]. Furthermore, the results from
the hydroelectrolytic study showed an increase in water intake and, al-
though not evaluated, a possible retention of sodium in animals treated
with AAS.We sought to examine autonomicmodulation (sympathetic–
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latter process.
The assessment of HRV performed in both the time and frequency
domains suggested that AAS treatment increased sympathetic modula-
tion and decreased parasympathetic modulation; thus, SDNN (ms) and
RMSSD (ms) signiﬁcantly decreased upon AAS treatment, which cor-
roborates the decreased parasympathetic modulation reported by
Aubert et al. [32]. In the spectral analysis, the predominance of sympa-
thetic modulation in the frequency domain was also observed in the
testosterone-treated group, which was suggested by the increase in
the ratio between the low- (LF) and high-frequency (HF) wave powers
(LF/HF). Pereira et al. [22] showed that supraphysiological AAS adminis-
tration, speciﬁcally of ND, altered cardiac autonomic control, damaging
parasympathetic control in rats. The authors also speculate that such
AAS-induced changes in cardiac autonomic controlmay trigger arrhyth-
mias or sudden death before signiﬁcant cardiovascular changes become
evident.
The hydroelectrolytic homeostasis and its physiological conse-
quences have been the focus of many studies. Water intake has often
been regarded as one of many regulatory mechanisms of body volume
and osmolality [75]. Several vasoactive peptides, in particular angioten-
sin II (ANG II), that circulate in plasma and are produced in various
tissues, including the brain [76], also act in the central nervous system
(CNS) by changing the water intake [77]. There are several central
peptidergic pathways capable of modulating water intake that may
play a role in blood pressure (BP) and osmotic regulation. These various
peptidergic systems may modulate water intake through changes in
baroreceptor function and regulation of extracellular ﬂuid osmolarity
[78].
In the present study, we showed that TP treatment during the pre-
pubertal phase (P26) of rats sufﬁced to alter the basal intake of ﬂuids to-
wards decreasing the intake/preference for sodium in the adult phase
(P90). In contrast to the sodium depletion paradigm, the animals in
the AAS group appear to have developed an exaggerated aversion to
1.8% NaCl at baseline conditions in the adult phase. A study conducted
by Rouah-Rosilio et al. [79] considers the existence of two morphologi-
cal and physiological substrates of the serotonergic system, which inte-
grates spontaneous and induced regulation of sodium intake. The
experiments performed by Yamada et al. [80] showed that neural
circuits that integrate the subfornical organ (SFO) and Raphe regions
(dorsal raphe nucleus (DRN) especially) would evoke responses intrin-
sic to the regulation of body ﬂuids. Additionally, testosterone induces an
increase in the ﬁring rate of serotonergic neurons by extracellular
recording in rats [81]. This observation is based on, at least partially,
the evidence obtained in the present work, whereas several reports in
the literature have shown that increased serotoninergic activity from
the DRN causes satiety for 1.8% NaCl, particularly in rats previously sub-
jected to the paradigm of the free choice between distilled water and
hypertonic saline [37,82]. However, the signiﬁcant reduction in the
preference for sodium should not be attributed solely to this midbrain
inhibitory mechanism. Therefore, sodium retention in this condition
could contribute to an aversion for sodium during chronic treatment
with testosterone. In this context, the direct upregulation of α-ENaC
mRNA expression by testosterone via the androgen receptor has been
demonstrated in vitro (human renal cell line HKC-8) and in vivo (rat
model) studies [83].
There is no data in literature concerning effects of prepubertally
androgen treatment in hydroelectrolytic balance of adult rats. It has
already been described that androgen treatment increased the expres-
sion/activity of peripheral renin–angiotensin system, e.g., upregulated
angiotensinogen gene expression, renin activity and AT1R expression
of adult rats [84–87]. Notwithstanding, there are evidences that intra-
muscular injection of testosterone decreases water intake in a model
of polyethylene glycol-induced hypovolemia in ovariectomized but
not in orquiectomized adult rats [33]. It remains unclear the possible
inﬂuence of androgens on the brain angiotensinergic system andcorrelated water and salt intake in different experimental paradigms,
as like this used herein.
In the present study, we found no statistically signiﬁcant differences
in relative liver weight between experimental groups. Some authors
report a correlation between the development of benign andmalignant
tumors in the liver with the use of AAS in the literature [88–91], which
could cause an increased weight. Perhaps such changes in relative liver
weight could occur over a longer treatment period. Studies conducted
by Sánchez-Osorio et al. [92] showed consistent results of increased
liver mass and increase of liver collagen deposition after prolonged
use of AAS. Liver structure and function may also be altered by the
administration of anabolic steroids, causing conditions including: chole-
static jaundice; peliosis hepatis; hepatocellular hyperplasia and hepato-
cellular adenoma [93,94]; and increased liver enzymes, including
aspartate aminotransferase, whichmay be observed in hepatic necrosis;
and increased risk for tumors in accordancewith the timeof exposure to
the drug [94].
We also found no statistically signiﬁcant differences in relative heart
weight between groups. Urhausen et al. [95] related the use of anabolic
steroids with changes in the cardiac muscle characterized by left ven-
tricular hypertrophy in a study with human subjects. Liu et al. [96]
also reported hypertrophy in rats and humans. Furthermore, studies
published in the literature have related AAS abuse by young male
athletes to various adverse cardiovascular effects [97–100]. The protocol
used for AAS administration in our study was most likely insufﬁcient to
induce signiﬁcant alterations (heart weight/cardiac hypertrophy) in our
model. However, it is worth noting that the same protocol sufﬁced to
alter the cardiac sympathetic–vagal balance towards increased sympa-
thetic modulation, a key generator of cardiac arrhythmias [101]. Thus,
from the translational standpoint, this study gains importance because
sudden death in AAS users who show no signiﬁcant cardiovascular
alterations relevant in routine examinations is not a rare occurrence
[102].
We found no statistically signiﬁcant differences in relative lung
weight between the study groups. This data also supports the hypothe-
sis that the protocol of AAS administration in this study failed to signif-
icantly affect the cardiovascular hemodynamics to the point of inducing
congestive heart failure or severe pulmonary arterial hypertension.
However, our protocol was capable of inducing subtle hydroelectrolytic
and autonomic alterations that may help to explain the occurrence of
sudden deaths in apparently healthy AAS users (athletes or not), even
when the abuse occurred only in the adolescence phase. Hemodynamic
studies in our model will be essential to strengthen this hypothesis.
In general, the results from this study enable us to conclude that AAS
treatment during a critical life period (adolescence)may cause irrevers-
ible behavioral, autonomic and hydroelectrolytic changes that may be
observed in the adult phase even when the AAS treatment is dis-
continued at the beginning of the adult phase.
Acknowledgments
This work was supported by grants from Fundação Carlos Chagas
Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ) and
Conselho Nacional de Desenvolvimento Cientíﬁco e Tecnológico
(CNPq).
References
[1] Kammerer RC. Drug testing and anabolic steroids. In: Yesalis CE, editor. Anabolic
steroids in sports and exercise, Champaign: human kinetics, 2nd ed.; 2000.
p. 415–59.
[2] Shahidi NT. A review of the chemistry, biological action, and clinical applications of
anabolic–androgenic steroids. Clin Ther 2001;23(9):1355–90.
[3] Sturmi JE, Diorio DJ. Anabolic agents. Clin Sports Med 1998;17(2):261–82.
[4] Denham BE. The Anabolic Steroid Control Act of 2004: a study in the political econ-
omy of drug policy. J Health Soc Policy 2006;22(2):51–78.
[5] Holland-Hall C. Performance-enhancing substances: is your adolescent patient
using? Pediatr Clin North Am 2007;54(4):651–62.
23E.L. Olivares et al. / Physiology & Behavior 126 (2014) 15–24[6] Pope Jr HG, Katz DL. Affective and psychotic symptoms associated with anabolic
steroid use. Am J Psychiatry 1988;145(4):487–90.
[7] Elliot D, Goldberg L. Intervention and prevention of steroid use in adolescents. Am J
Sports Med 1996;24(6):46–7.
[8] Farrell SF, Mcginnis MY. Long-term effects of pubertal anabolic–androgenic steroid
exposure on reproductive and aggressive behaviors in male rats. Horm Behav
2004;46(2):193–203.
[9] Farrell SF, McGinnis MY. Effects of pubertal anabolic–androgenic steroid (AAS)
administration on reproductive and aggressive behaviors in male rats. Behav
Neurosci 2003;117(5):904–11.
[10] Dickerman RD, Schaller F, Prather I, McConathy WJ. Sudden cardiac death in a 20-
year-old bodybuilder using anabolic steroids. Cardiology 1995;86(2):172–3.
[11] Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E. Anabolic steroid
abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med
2001;125(2):253–5.
[12] Hausmann R, Hammer S, Betz P. Performance enhancing drugs (doping agents)
and sudden death — a case report and review of the literature. Int J Legal Med
1998;111(5):261–4.
[13] Luke DR, Brunner LJ, Vadiei K. Bioavailability assessment of cyclosporine in the rat.
Inﬂuence of route of administration. Drug Metab Dispos 1990;18(2):158–62.
[14] De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E. Anabolic steroid use in body
builders: an echocardiographic study of left ventricle morphology and function.
Int J Sports Med 1991;12(4):408–12.
[15] Pearson AC, Schiff M, Mrosek D, Labovitz AJ, Williams GA. Left ventricular diastolic
function in weight lifters. Am J Cardiol 1986;58(13):1254–9.
[16] Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, et al.
Serious cardiovascular side effects of large doses of anabolic steroids in weight
lifters. Eur Heart J 1996;17(10):1576–83.
[17] Thiblin I, Lindquist O, Rajs J. Cause and manner of death among users of anabolic
androgenic steroids. J Forensic Sci 2000;45(1):16–23.
[18] Freed DLJ, Banks AJ, Longson D, Burley DM. Anabolic steroids in athletics: crossover
double-blind trial on weightlifters. BMJ 1975;2(5969):471–3.
[19] Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, Van 't Laar A, et al. Dele-
terious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver
function in amateur body builders. Int J Sports Med 1988;9(1):19–23.
[20] Sullivan ML, Martinez CM, Gennis P, Gallagher EJ. The cardiac toxicity of anabolic
steroids. Prog Cardiovasc Dis 1998;41(1):1–15.
[21] Thiblin I, Mobini-Far H, Frisk M. Sudden unexpected death in a female ﬁtness
athlete, with a possible connection to the use of anabolic androgenic steroids
(AAS) and ephedrine. Forensic Sci Int 2009;184(1–3):7–11.
[22] Pereira JRPP, Chaves EA, Costa-e-Sousa RH, Masuda MO, Carvalho AC, Nascimento
JH. Cardiac autonomic dysfunction in rats chronically treated with anabolic steroid.
Eur J Appl Physiol 2006;96(5):487–94.
[23] Kennedy HL. Beta blockade, ventricular arrhythmias, and sudden cardiac death. Am
J Cardiol 1997;80(9B):29J–34J.
[24] Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experi-
mental evidence of its relationship with the sympathetic nervous system and
with the long Q–T syndrome. Am Heart J 1975;89(1):45–50.
[25] Nohara K, Waraich RS, Liu S, Ferron M, Waget A, Meyers MS, et al. Developmental
androgen excess programs sympathetic tone and adipose tissue dysfunction and
predisposes to a cardiometabolic syndrome in female mice. Am J Physiol
Endocrinol Metab 2013;304(12):E1321–30.
[26] Sisk CL, Foster DL. The neural basis of puberty and adolescence. Nat Neurosci
2004;7(10):1040–7.
[27] Cunningham RL, Mcginnis MY. Prepubertal social subjugation and anabolic andro-
genic steroid-induced aggression in male rats. J Neuroendocrinol 2008;20(8):
997–1005.
[28] Olivares EL, Silva-Almeida C, Pestana FM, Sonoda-Côrtes R, Araujo IG, Rodrigues NC,
et al. Social stress-induced hypothyroidism is attenuated by antidepressant treat-
ment in rats. Neuropharmacology 2012;62(1):446–56.
[29] Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an
elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods
1985;14(3):149–67.
[30] Violle N, Balandras F, Le Roux Y, Desor D, Shoereder H. Variations in illumination,
closed wall transparency and/or extramaze space inﬂuence both baseline anxiety
and response to diazepam in the rat elevated plus-maze. Behav Brain Res
2009;203(1):35–42.
[31] Prickaerts J, Raaijmakers W, Blokland A. Effects of myocardial infarction and capto-
pril therapy on anxiety-related behaviors in the rat. Physiol Behav 1996;60(1):
43–50.
[32] Aubert AE, Ramaekers D, Beckers F, Breem R, Denef C, Van de Werf F, et al. The
analysis of heart rate variability in unrestrained rats. Validation of method and
results. Comput Methods Programs Biomed 1999;60(3):197–213.
[33] Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol Rev 1998;78(3):
583–686.
[34] Badauê-Passos Jr D, Ventura RR, Silva LFS, Olivares EL, Reis LC. Effect of brain sero-
toninergic stimulation on sodium appetite of euthyroid and hypothyroid rats. Exp
Physiol 2003;88(2):251–60.
[35] Olivares EL, Costa-e-Sousa RH, Cavalcante-Lima HR, Lima HR, Cedraz-Mercez PL,
Reis LC. Effect of electrolytic lesion of the dorsal raphe nucleus on water intake
and sodium appetite. Braz J Med Biol Res 2003;36(12):1709–16.
[36] Cavalcante-Lima HR, Badauê-Passos Jr D, De-Lucca JRW, Lima HRC, Costa-e-Sousa
RH, Olivares EL, et al. Chronic excitotoxic lesion of dorsal raphe nucleus induces
sodium appetite. Braz J Med Biol Res 2005;38(11):1669–75.
[37] Reis LC. Role of the serotoninergic system in the sodium appetite control. An Acad
Bras Cienc 2007;79(2):261–83.[38] Noorafshan A, Karimipoor M, Bahmanpoor S, Dehghani F. The inﬂuence of expo-
sure to stress of pregnant rats on the adrenal gland structure of their offspring.
An unbiased stereological study. Scand J Lab Anim Sci 2005;32(3):161–6.
[39] Hall RC, Hall RC, Chapman MJ. Psychiatric complications of anabolic steroid abuse.
Psychosomatics 2005;46(4):285–90.
[40] Breuer ME, Mcginnis MY, Lumia AR, Possidente BP. Aggression in male rats receiv-
ing anabolic androgenic steroids: effects of social and environmental provocation.
Horm Behav 2001;40(3):409–18.
[41] Lumia AR, Thorner KM, McGinnis MY. Effects of chronically high doses of the ana-
bolic androgenic steroid, testosterone, on intermale aggression and sexual behavior
in male rats. Physiol Behav 1994;55(2):331–5.
[42] McGinnis MY, Lumia AR, Breuer ME, Possidente B. Physical provocation potentiates
aggression in male rats receiving anabolic androgenic steroids. Horm Behav
2002;41(1):101–10.
[43] Long SF, Wilson MC, Sufka KJ, Davis WM. The effects of cocaine and nandrolone co-
administration on aggression in male rats. Prog Neuropsychopharmacol Biol
Psychiatry 1996;20(5):839–56.
[44] Lindqvist AS. Anabolic androgenic steroid affects competitive behaviour, behav-
ioural response to ethanol and brain serotonin levels. Behav Brain Res 2001;
133(1):21–9.
[45] McGinnis MY. Anabolic androgenic steroids and aggression: studies using animal
models. Ann N Y Acad Sci 2004;1036:399–415.
[46] Clark AS, Harrold EV, Fast AS. Anabolic–androgenic steroid effects on the sexual
behavior of intact male rats. Horm Behav 1997;31(1):35–46.
[47] Salas-Ramirez KY, Montalto PR, Sisk CL. Anabolic androgenic steroids differentially
affect social behaviors in adolescent and adult male Syrian hamsters. Horm Behav
2008;53(2):378–85.
[48] Clark S, Henderson L. Behavioral and physiological responses to anabolic–andro-
genic steroids. Neurosci Biobehav Rev 2003;27(5):413–36.
[49] Brooks JH, Reddon JR. Serum testosterone in violent and nonviolent young of-
fenders. J Clin Psychol 1996;52(4):475–83.
[50] Tricker R, Casaburi R, Storer TW, Clevenger B, Berman N, Shirazi A, et al. The effects
of supraphysiological doses of testosterone on angry behavior in healthy eugonadal
males — a clinical research center study. J Clin Endocrinol Metab 1996;81(10):
3754–8.
[51] Wang MG, Yesalis CE, Fitzhygh EC. Desire for weight gain and potential risks of
adolescent males using anabolic steroids. Percept Mot Skills 1994;78(1):267–74.
[52] Kindlundh AM, BergströmM, Monazzam A, Hallberg M, Blomqvist G, Långström B,
et al. Dopaminergic effects after chronic treatment with nandrolone visualized in
rat brain by positron emission tomography. Prog Neuropsychopharmacol Biol
Psychiatry 2002;26(7–8):1303–8.
[53] Rygula R, Abumaria N, Flügge G, Fuchs E, Rüther E, Havemann-Reinecke U.
Anhedonia and motivational deﬁcits in rats: impact of chronic social stress.
Behav Brain Res 2005;162(1):127–34.
[54] Buddenberg TE, komorowski M, Ruocco LA, Silva MA, Topic B. Attenuating effects of
testosterone on depressive-like behavior in the forced swim test in healthy male
rats. Brain Res Bull 2009;79(3–4):182–6.
[55] Bing O, Heilig M, Kakoulidis P, Sundblad C,Wiklund L, Eriksson E. High doses of tes-
tosterone increase anticonﬂict behaviour in rat. Eur Neuropsychopharmacol
1998;8(4):321–3.
[56] Bitran D, Kellogg CK, Hilvers RJ. Treatment with an anabolic–androgenic steroid
affects anxiety-related behavior and alters the sensitivity of cortical GABA A recep-
tors in the rat. Horm Behav 1993;27(4):568–83.
[57] Bronson FH. Effects of prolonged exposure to anabolic steroids on the behavior of
male and female mice. Pharmacol Biochem Behav 1996;53(2):329–34.
[58] Clark AS, Fast AS. Comparison of the effects of 17a-methyltestosterone,
methandrostenolone, and nandrolone decanoate on the sexual behavior of castrat-
ed male rats. Behav Neurosci 1996;110(6):1478–86.
[59] Clark AS, Harrold EV. Comparison of the effects of stanozolol, oxymetholone, and
testosterone cypionate on the sexual behavior of castrated male rats. Behav
Neurosci 1997;111(6):1368–74.
[60] Salvador A,Moya-Albiol L, Martínez-Sanchis S, Simón VM. Lack of effects of anabolic-
androgenic steroids on locomotor activity in intact male mice. Percept Mot Skills
1999;88(1):319–28.
[61] Martínez-Sanchis S, Brain PF, Salvador A, Simón VM. Long-term chronic treatment
with stanozolol lacks signiﬁcant effects on aggression and activity in young and
adult male laboratory mice. Gen Pharmacol 1996;27(2):293–8.
[62] Martínez-Sanchis S, Aragon CM, Salvador A. Cocaine-induced locomotor activity is
enhanced by exogenous testosterone. Physiol Behav 2002;76(4–5):605–9.
[63] Minkin DM, Meyer ME, Van Haaren F. Behavioral effects of longterm administra-
tion of an anabolic steroid in intact and castrated male Wistar rats. Pharmacol
Biochem Behav 1993;44(4):959–63.
[64] Ramos A, Pereira E, Martins GC, Wehrmeister TD, Izidio GS. Integrating the open
ﬁeld, elevated plus maze and light/dark box to assess different types of emotional
behaviors in one single trial. Behav Brain Res 2008;193(2):277–88.
[65] Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a
maze-explorationmodel of ‘fear’-motivated behavior. Naunyn Schmiedebergs Arch
Pharmacol 1984;327(1):1–5.
[66] Kuhn CM. Anabolic steroids. Recent Prog Horm Res 2002;57:411–34.
[67] Rocha VM, Calil CM, Ferreira R, Moura MJ, Marcondes FK. Inﬂuence of anabolic ste-
roid on anxiety levels in sedentary male rats. Stress 2007;10(4):326–31.
[68] Kouvelas D, Pourzitaki C, Papazisis G, Dagklis T, Dimou K, Kraus MM. Nandrolone
abuse decreases anxiety and impairs memory in rats via central androgenic recep-
tors. Int J Neuropsychopharmacol 2008;11(7):925–34.
[69] Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress
report. Pharmacol Rev 2004;56(1):31–52.
24 E.L. Olivares et al. / Physiology & Behavior 126 (2014) 15–24[70] De Angelis K, Wichi RB, Jesus WRA, Moreira ED, Morris M, Krieger EM, et al. Exer-
cise training changes autonomic cardiovascular balance in mice. J Appl Physiol
2004;96(6):2174–8.
[71] Beutel A, Bergamaschi CT, Campos RR. Effects of chronic anabolic steroid treatment
on tonic and reﬂex cardiovascular control in male rats. J Steroid Biochem Mol Biol
2005;93(1):43–8.
[72] Phillis BD, Abeywardena MY, Adams MJ, Kennedy JA, Irvine RJ. Nandrolone poten-
tiates arrhythmogenic effects of cardiac ischemia in the rat. Toxicol Sci 2007;99(2):
605–11.
[73] Shaji AV, Kulkarni SK. Evidence of GABAergic modulation in melatonin-induced
short-term memory deﬁcits and food consumption. Methods Find Exp Clin
Pharmacol 1998;20(4):311–9.
[74] Inagaki H, Kuwahara M, Tsubone H. Effects of psychological stress on autonomic
control of heart in rats. Exp Anim 2004;53(4):373–8.
[75] Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, et al. The pressor response to
water drinking in humans: a sympathetic reﬂex? Circulation 2000;101(5):504–9.
[76] Standaert DG, Needleman P, Day ML, Weigand R, Krause JE. Expression of the gene
for preproatriopeptin in the central nervous system of the rat. Brain Res
1988;464(1):7–13.
[77] Samson WK, Skala KD, Huang FL. CNP-22 stimulates, rather than inhibits, water
drinking in the rat: evidence for a unique biological action of the C-type natriuretic
peptides. Brain Res 1991;24(568(1–2)):285–8.
[78] Murphy TC, Samson WK. The novel vasoactive hormone, adrenomedullin, inhibits
water drinking in the rat. Endocrinology 1995;136(6):2459–63.
[79] Rouah-Rosilio M, Orosco M, Nicolaidis S. Serotoninergic modulation of sodium
appetite in the rat. Physiol Behav 1994;55(5):811–6.
[80] Yamada S, HaranoM, TanakaM. Dopamine autoreceptors in rat nucleus accumbens
modulate prepulse inhibition of acoustic startle. Pharmacol Biochem Behav
1998;60(4):803–8.
[81] Robichaud M, Debonnel G. Oestrogen and testosterone modulate the ﬁring activity
of dorsal raphe nucleus serotonergic neurones in both male and female rats.
J Neuroendocrinol 2005;17(3):179–85.
[82] Fonseca FV, Mecawi AS, Araujo IG, Almeida-Pereira G, Magalhães-Nunes AP,
Badauê-Passos Jr D, et al. Role of the 5-HT1A somatodendritic autoreceptor in the
dorsal raphe nucleus on salt satiety signaling in rats. ExpNeurol 2009;217(2):353–60.
[83] Quinkler M, Bujalska IJ, Kaur K, Onyimba CU, Buhner S, Allolio B, et al. Androgen
receptor-mediated regulation of the alpha-subunit of the epithelial sodium chan-
nel in human kidney. Hypertension 2005;46(4):787–98.
[84] Ellison KE, Ingelﬁnger JR, Pivor M, Dzau VJ. Androgen regulation of rat renal
angiotensinogen messenger RNA expression. J Clin Invest 1989;83(6):1941–5.[85] Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin
messenger RNA expression in hypertensive rats. Hypertension 1992;19(5):
456–63.
[86] Johnston CI, Fabris B, Jandeleit K. Intrarenal renin–angiotensin system in renal
physiology and pathophysiology. Kidney Int Suppl 1993;42:S59–63.
[87] Hilliard LM, Sampson AK, Brown RD, Denton KM. The “his and hers” of the renin–
angiotensin system. Curr Hypertens Rep 2013;15(1):71–9.
[88] Watanabe S, Kobayashi Y. Exogenous hormones and human cancer. J Clin Oncol
1993;23(1):1–13.
[89] Soe KL, Soe M, Gluud CN. Liver pathology associated with anabolic–androgenic
steroids. Ugeskr Laeger 1994;156(17):2585–8.
[90] Friedl R, Brunner M, Moeslinger T, Spieckermann PG. Testosterone inhibits expres-
sion of inducible nitric oxide synthase inmurine macrophages. Life Sci 2000;68(4):
417–29.
[91] Velazquez I, Alter BP. Androgens and liver tumors: Fanconi's conditions. Am J
Hematol 2004;77(3):257–67.
[92] Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre A, Uribe M. Anabolic–
androgenic steroids and liver injury. Liver Int 2008;28(2):278–82.
[93] Labree MA. A review of anabolic steroids: uses and effects. J Sports Med Phys Fit-
ness 1991;31(4):618–26.
[94] Lise MLZ, Gama e Silva TS, Ferigolo M, Barros HMT. O abuso de esteróides
anabólicos androgênicos em atletismo. Rev Assoc Med Bras 1999;45(4):364–70.
[95] Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid
abuse in strength athletes reversible? Heart 2004;90(5):496–501.
[96] Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr
Rev 2003;24(3):313–40.
[97] Falkenberg M, Karlsson J, Örtenwall P. Peripheral arterial thrombosis in two young
men using anabolic steroids. Eur J Vasc Endovasc Surg 1997;13(2):223–6.
[98] Ferrera PC, Putnam DL, Verdile VP. Anabolic steroid use as the possible precipitant
of dilated cardiomyopathy. Cardiology 1997;88(2):218–20.
[99] Di Bello V, Giorgi D, Bianchi M, Bertini A, Caputo MT, Valenti G, et al. Effects of
anabolic–androgenic steroids on weight-lifters' myocardium: an ultrasonic video
densitometric study. Med Sci Sports Exerc 1999;31(4):514–21.
[100] McCarthy K, Tang ATM, Dalrymple-Hay MJR, Haw MP. Ventricular thrombosis and
systemic embolism in bodybuilders: etiology and management. Ann Thorac Surg
2000;70(2):658–60.
[101] Hautala AJ, Kiviniemi AM, Tulppo MP. Individual responses to aerobic exercise:
the role of the autonomic nervous system. Neurosci Biobehav Rev 2009;33(2):
107–15.
[102] Bowman S. Anabolic steroids and infarction. BMJ 1990;300(6726):750.
